Candidats a vaccí contra la Covid-19, segons l'Organització Mundial de la Salut

DRAFT landscape of COVID-19 candidate vaccines – 15 May 2020 8 candidate vaccines in clinical evaluation Platform

Type of candidate vaccine

Developer

Coronavirus target

Current stage of clinical evaluation/regulatory statusCoronavirus candidate

Same platform for non-Coronavirus candidates

NonReplicating Viral Vector

Adenovirus Type 5 Vector

CanSino Biological Inc./Beijing Institute of Biotechnology

SARS-CoV2

Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906

Ebola

RNA

LNPencapsulated mRNA

Moderna/NIAID

SARS-CoV2

Phase 2 (IND accepted) Phase 1 NCT04283461

multiple candidates

Inactivated

Inactivated

SARS-CoV2

Phase 1/2 ChiCTR2000031809

Inactivated

Inactivated

Wuhan Institute of Biological Products/Sinopharm Beijing Institute of Biological Products/Sinopharm

SARS-CoV2

Phase 1/2 ChiCTR2000032459

Inactivated

Inactivated + alum

Sinovac

SARS-CoV2

Phase 1/2 NCT04352608

SARS

NonReplicating Viral Vector

ChAdOx1

University of Oxford

SARS-CoV2

Phase 1/2 NCT04324606

MERS, influenza, TB, Chikungunya, Zika, MenB, plague

RNA

3 LNP-mRNAs

BioNTech/Fosun Pharma/Pfizer

SARS-CoV2

Phase 1/2 2020-001038-36 NCT04368728

DNA

DNA plasmid vaccine with electroporation

Inovio Pharmaceuticals

SARS-CoV2

Phase 1 NCT04336410

multiple candidates

110 candidate vaccines in preclinical evaluation Platform

SARS-CoV2

SARS-CoV2

Pre-Clinical

SARS-CoV2 SARS-CoV2

Pre-Clinical Pre-Clinical

DNA

Karolinska Institute / Cobra Biologics (OPENCORONA Project) DNA plasmid vaccine Osaka University/ AnGes/ Takara Bio DNA Takis/Applied DNA Sciences/Evvivax Plasmid DNA, Immunomic Therapeutics, Needle-Free Delivery Inc./EpiVax, Inc./PharmaJet DNA plasmid vaccine Zydus Cadila

Current stage of clinical evaluation/regulatory status- Coronavirus candidate Pre-Clinical

SARS-CoV2

Pre-Clinical

DNA DNA DNA DNA Inactivated

DNA vaccine DNA vaccine DNA vaccine bacTRL-Spike Inactivated

SARS-CoV2 SARS-CoV2 SARS-CoV2 SARS-CoV2 SARS-CoV2

Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical

Inactivated

TBD

SARS-CoV2

Pre-Clinical

DNA

DNA DNA DNA

Type of candidate vaccine

Developer

DNA with electroporation

BioNet Asia University of Waterloo Entos Pharmaceuticals Symvivo Institute of Medical Biology , Chinese Academy of Medical Sciences Osaka University/ BIKEN/ NIBIOHN

Coronavirus target

Same platform for nonCoronavirus candidates

SARS

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Inactivated Inactivated Inactivated Live Attenuated Virus Live Attenuated Virus NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector Nonreplicating viral vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector NonReplicating Viral Vector Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit

Inactivated + CpG 1018 Inactivated + CpG 1018 Inactivated

Sinovac/Dynavax

SARS-CoV2

Pre-Clinical

Valneva/Dynavax

SARS-CoV2

Pre-Clinical

Research Institute for Biological SARS-CoV2 Safety Problems, Rep of Kazakhstan Codagenix/Serum Institute of India SARS-CoV2

Pre-Clinical

Indian Immunologicals Ltd/Griffith University

SARS-CoV2

Pre-Clinical

GeoVax/BravoVax

SARS-CoV2

Pre-Clinical

LASV, EBOV, MARV, HIV

Janssen Pharmaceutical Companies

SARS-CoV2

Pre-Clinical

Ebola, HIV, RSV

Replication defective ReiThera/LEUKOCARE/Univercells Simian Adenovirus (GRAd) encoding SARS-CoV-2 S MVA-S encoded DZIF – German Center for Infection Research

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-clinical

Many

adenovirus-based NasoVAX expressing SARS2-CoV spike protein Ad5 S (GREVAX™ platform)

Altimmune

SARS-CoV2

Pre-Clinical

influenza

Greffex

SARS-CoV2

Pre-Clinical

MERS

Oral Ad5 S

Stabilitech Biopharma Ltd

SARS-CoV2

Pre-Clinical

Zika, VZV, HSV2 and Norovirus

adenovirus-based + HLA-matched peptides Oral Vaccine platform

Valo Therapeutics Ltd

Pan-Corona

Pre-Clinical

Vaxart

SARS-CoV2

Pre-Clinical

MVA expressing structural proteins

Centro Nacional Biotecnología (CNB-CSIC), Spain

SARS-CoV2

Pre-Clinical

Dendritic cell-based vaccine

University of Manitoba

SARS-CoV2

Pre-Clinical

parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein Recombinant deactivated rabies virus containing S1 Capsid-like Particle

University of Georgia/University of Iowa

SARS-CoV2

Pre-Clinical

MERS

Bharat Biotech/Thomas Jefferson University

SARS-CoV2

Pre-Clinical

HeV, NiV, EBOV, LASSA, CCHFV, MERS

AdaptVac (PREVENT-nCoV consortium) ExpreS2ion

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

IMV Inc

SARS-CoV2

Pre-Clinical

WRAIR/USAMRIID

SARS-CoV2

Pre-Clinical

National Institute of Infectious Disease, Japan

SARS-CoV2

Pre-Clinical

Codon deoptimized live attenuated vaccines Codon deoptimized live attenuated vaccines MVA encoded VLP

Ad26

Drosophila S2 insect cell expression system VLPs Peptide antigens formulated in LNP S protein S protein +Adjuvant

Pre-Clinical

HAV, InfA, ZIKV, FMD, SIV, RSV, DENV

InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE Multiple candidates

Influenza

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Protein Subunit

VLP-recombinant protein + Adjuvant

Protein Subunit

Native like Trimeric subunit Spike Protein vaccine microneedle arrays S1 subunit Peptide

Protein Subunit Protein Subunit Protein Subunit Protein Subunit

Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit

Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit

Protein Subunit Protein Subunit Protein Subunit

Protein Subunit

Protein Subunit

Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan Clover Biopharmaceuticals Inc./GSK/Dynavax

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

HIV, REV Influenza

Univ. of Pittsburgh

SARS-CoV2

Pre-Clinical

MERS

Vaxil Bio

SARS-CoV2

Pre-Clinical

Adjuvanted protein subunit (RBD) Peptide

Biological E Ltd

SARS-CoV2

Pre-Clinical

Flow Pharma Inc

SARS-CoV2

Pre-Clinical

S protein

AJ Vaccines

SARS-CoV2

Pre-Clinical

Ii-Key peptide

Generex/EpiVax

SARS-CoV2

Pre-Clinical

S protein

EpiVax/Univ. of Georgia

SARS-CoV2

Pre-Clinical

S protein Sanofi Pasteur/GSK (baculovirus production) Full length Novavax recombinant SARs CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M gp-96 backbone Heat Biologics/Univ. Of Miami

SARS-CoV2

Pre-Clinical

Influenza, SARS-CoV

SARS-CoV2

Pre-Clinical

RSV; CCHF, HPV, VZV, EBOV

SARS-CoV2

Pre-Clinical

Molecular clamp stabilized Spike protein Peptide vaccine

University of Queensland/GSK/Dynavax

SARS-CoV2

Pre-Clinical

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo Baylor College of Medicine

SARS-CoV2

Pre-Clinical

NSCLC, HIV, malaria, Zika Nipah, influenza, Ebola, Lassa Ebola

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

iBio/CC-Pharming

SARS-CoV2

Pre-Clinical

Saint-Petersburg scientific research institute of vaccines and serums

SARS-CoV2

Pre-Clinical

Innovax/Xiamen Univ./GSK

SARS-CoV2

Pre-Clinical

VIDO-InterVac, University of Saskatchewan OncoGen

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

MIGAL Galilee Research Institute

SARS-CoV2

Pre-Clinical

LakePharma, Inc.

SARS-CoV2

Pre-Clinical

Subunit vaccine S1 or RBD protein Subunit protein, plant produced Recombinant protein, nanoparticles (based on S-protein and other epitopes) COVID-19 XWG-03 truncated S (spike) proteins Adjuvanted microsphere peptide Synthetic Long Peptide Vaccine candidate for S and M proteins Oral E. coli-based protein expression system of S and N proteins Nanoparticle vaccine

Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine

Influenza, HIV, SARS-CoV H7N9

SARS

HPV

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit Protein Subunit

Protein Subunit Protein Subunit Replicating Viral Vector Replicating Viral Vector Replicating Viral Vector Replicating Viral Vector Live attenuated virus Replicating Viral Vector Replicating Viral Vector

Replicating Viral Vector

Replicating Viral Vector Replicating Viral Vector

Replicating Viral Vector Replicating Viral Vector

Recombinant spike Vaxine Pty Ltd protein with Advax™ adjuvant OMV-based vaccine Quadram Institute Biosciences

SARS-CoV2

OMV-based vaccine

BiOMViS Srl/Univ. of Trento

SARS-CoV2

Spike-based

University of Alberta

SARS-CoV2

Pre-Clinical

Recombinant S1-Fc fusion protein Recombinant protein Recombinant S protein in IC-BEVS Orally delivered, heat stable subunit S-2P protein + CpG 1018 Peptides derived from Spike protein Adjuvanted recombinant protein (RBD-Dimer)

AnyGo Technology

SARS-CoV2

Pre-Clinical

Yisheng Biopharma

SARS-CoV2

Pre-Clinical

Vabiotech

SARS-CoV2

Pre-Clinical

Applied Biotechnology Institute, Inc. Medigen Vaccine Biologics Corporation/NIAID/Dynavax Axon Neuroscience SE

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences Neovii/Tel Aviv University

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

Outer Membrane Vesicle (OMV)peptide YF17D Vector

Intravacc/Epivax

SARS-CoV2

Pre-Clinical

KU Leuven

SARS-CoV2

Pre-Clinical

Measles Vector

Zydus Cadila

SARS-CoV2

Pre-Clinical

Measles Vector

Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo DZIF – German Center for Infection Research

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-clinical

Zika, H7N9, CHIKV

Horsepox vector expressing S protein Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) Influenza vector expressing RBD Replicationcompetent VSV chimeric virus technology (VSVΔG) delivering the SARSCoV-2 Spike (S) glycoprotein.

VSV-S

Tonix Pharma/Southern Research

SARS-CoV2

Pre-Clinical

BiOCAD and IEM

SARS-CoV2

Pre-Clinical

Smallpox, monkeypox Influenza

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

Influenza

University of Hong Kong

SARS-CoV2

Pre-Clinical

IAVI/Batavia

SARS-CoV2

Pre-Clinical

Ebola, Marburg, Lassa

University of Western Ontario

SARS-CoV2

Pre-Clinical

HIV, MERS

VSV vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

SARS-CoV2

Pre-Clinical

RBD-based

Measles Vector Measles Virus (S, N targets)

Pre-Clinical

SARS-CoV2

Flu A, plague

Hepatitis C

West nile, chik, Ebola, Lassa, Zika

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Replicating Viral Vector

UW–Madison/FluGen/Bharat Biotech

SARS-CoV2

Pre-Clinical

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.

The Lancaster University, UK

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2 SARS-CoV2

Pre-Clinical Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

SARS-CoV2

Pre-Clinical

RNA

Translate Bio/Sanofi Pasteur Fudan University/ Shanghai JiaoTong University/RNACure Biopharma Fudan University/ Shanghai JiaoTong University/RNACure Biopharma Replicating Centro Nacional Biotecnología Defective SARS-CoV- (CNB-CSIC), Spain 2 derived RNAs LNP-encapsulated University of Tokyo/ Daiichi-Sankyo mRNA LiposomeBIOCAD encapsulated mRNA Several mRNA RNAimmune, Inc. candidates mRNA FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo mRNA China CDC/Tongji University/Stermina mRNA Arcturus/Duke-NUS

SARS-CoV2

Pre-Clinical

multiple candidates

RNA

saRNA

Imperial College London

SARS-CoV2

Pre-Clinical

RNA

mRNA

Curevac

SARS-CoV2

Pre-Clinical

EBOV; LASV, MARV, Inf (H7N9), RABV RABV, LASV, YFV; MERS, InfA, ZIKV, DengV, NIPV

RNA

mRNA in an intranasal delivery system mRNA

eTheRNA

SARS-CoV2

Pre-Clinical

Greenlight Biosciences

SARS-CoV2

Pre-Clinical

Virus-like particle, based on RBD displayed on viruslike particles Plant-derived VLP

Saiba GmbH

SARS-CoV2

Pre-Clinical

Medicago Inc.

SARS-CoV2

Pre-Clinical

Imophoron Ltd and Bristol University’s Max Planck Centre Doherty Institute

SARS-CoV2

Pre-Clinical

VLP

ADDomerTM multiepitope display Unknown

SARS-CoV2

Pre-Clinical

VLP

VLP

OSIVAX

Pre-Clinical

VLP

eVLP

ARTES Biotechnology

SARS-CoV1 SARS-CoV2 SARS-CoV2

VLP

SARS-CoV2

Pre-Clinical

Unknown

VLPs peptides/whole Univ. of Sao Paulo virus Unknown ImmunoPrecise

SARS-CoV2

Pre-Clinical

Unknown

Unknown

Tulane University

SARS-CoV2

Pre-Clinical

Unknown

Unknown

Université Laval

SARS-CoV2

Pre-Clinical

Replicating Viral Vector Replicating Viral Vector RNA RNA

RNA

RNA

RNA RNA RNA RNA RNA

RNA VLP

VLP

VLP

M2-deficient single replication (M2SR) influenza vector Newcastle disease virus vector (NDVSARS-CoV-2/Spike) Avian paramyxovirus vector (APMV) LNP-mRNA LNP-encapsulated mRNA cocktail encoding VLP LNP-encapsulated mRNA encoding RBD

Pre-Clinical

influenza

MERS

Flu, Rotavirus, Norovirus, West Nile virus, Cancer

malaria

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.